Literature DB >> 33067948

[Expression of Hsa-miR-9 in Children with Acute Lymphoblastic Leukemia and Its Relationship with CDX2 Gene].

Rui-Cang Wang1, Jie Yang2, Xiao-Xia Zhang1, Xiao-Han Gao1.   

Abstract

OBJECTIVE: To investigate the expression of Hsa-miR-9 in children with acute lymphoblastic leukemia (ALL) and its relationship with CDX2 gene.
METHODS: The clinical data of 130 patients with ALL were collected from nearly five years in our hospital, and in the same period 60 healthy children in the same age were selected as control group. Real-time fluorescent quantitative PCR (qRT-PCR) was applied to examine the expression of Hsa-miR-9 and CDX2 gene of the two groups, the relationship between Hsa-miR-9 expression and ALL patients' clinical characteristics, survival time, CDX2 expression were analyzed.
RESULTS: The expression level of Hsa-miR-9 in ALL children was significantly lower than that in the healthy control group (P<0.001). The expression of Hsa-miR-9 in ALL children related with serum WBC, infiltrating lymph nodes, splenomegaly, and risk grade (P<0.05). The median survival time of ALL children with high expression of Hsa-miR-9 was significantly longer than that of the ALL children with low expression (P<0.001). Hsa-miR-9 expression significantly correlated with CDX2 gene expression in ALL children at different treatment stages (P<0.05).
CONCLUSION: The expression of Hsa-miR-9 decreases in children with ALL, and ALL children with high expression of Hsa-miR-9 have a longer overall survival time. The expression of hsa-miR-9 in ALL children closely related with CDX2 gene.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33067948     DOI: 10.19746/j.cnki.issn.1009-2137.2020.05.016

Source DB:  PubMed          Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi        ISSN: 1009-2137


  1 in total

1.  Value of serum miR-922 and miR-506 expression levels in the diagnosis and prognostic assessment of childhood acute lymphoblastic leukemia.

Authors:  Yi-Yue Zhu; Ri-Nuan Wu; Xia Li; Xiang-Bi Chen
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2021-10-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.